DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

Thursday, June 15, 2017 8:31 PM UTC

AMF REGULATED INFORMATION
Montrouge, France, June 15, 2017

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General
Meeting

Shareholders approve all proposed resolutions

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today held its Ordinary and Extraordinary General Meeting, which was chaired by Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies.

At the General Meeting, the Company's shareholders approved all resolutions submitted by the Board of Directors. These resolutions are posted on the Investor Relations section of the Company's website, http://www.dbv-technologies.com/en/investor-relations.

About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
[email protected]

Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
[email protected]

Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
[email protected]

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/f752fddb-de88-428a-ae7c-c4e205eebf62

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

Editor's Picks

Welcome to EconoTimes